Summer Master

Circassia Ltd, a specialty
biopharmaceutical company focused on the fields of allergy and critical
care, today announced the start of a further phase II clinical study of its
ToleroMune(R) technology in the field of cat allergy. The trial builds on
positive results achieved in an earlier phase II study, which demonstrated
the potential clinical benefits of the ToleroMune approach to allergy
desensitization.
In the previous phase II clinical trial, patients experienced
substantially reduced reactions to cat allergens after a single
administration of ToleroMune therapy. The current study builds on this
work, and will explore different 4-dose treatment regimens, which are
designed to enhance the patients’ response and determine the best
therapeutic approach. During the study, patients will receive a controlled
dose of cat allergen in an environmental exposure chamber both before and
after treatment, and will then complete a questionnaire to score their
allergic rhinitis symptoms. This will allow investigators to evaluate the
impact of the different treatment regimes. The double-blind, randomized,
placebo-controlled trial will include a total of 120 volunteers with
confirmed cat allergies. The study, which is already underway in Canada, is
progressing well with approximately 20% of patients enrolled for screening
so far.
"This study is of great importance for Circassia as it is designed to
define the most effective treatment regime for our ToleroMune allergy
products, and in particular for the phase III studies of our cat-allergy
therapy that are planned to begin in the second half of 2009," said Steve
Harris, Circassia’s CEO. "The results of our trials to date show that our
ToleroMune approach offers patients substantial potential benefits.
Conventional allergy treatments either address symptoms only or require
many doses over a period of months under specialist supervision because
they can result in serious, even life-threatening adverse reactions. In
contrast, Circassia’s anti-allergy technology has the potential to provide
effective but shorter treatments, while minimizing the threat of severe
side-effects."
About Circassia
Circassia is a specialty biopharmaceutical company focused on the
fields of allergy and critical care. The company has a highly experienced
management team with a proven track record in product development and
commercialization, and having successfully completed two fundraising rounds
is backed by a syndicate of world-class venture capital and institutional
investors, including Imperial Innovations, Lansdowne Partners, Goldman
generic zithromax online buy Sachs and Invesco Perpetual.
Circassia’s lead products target allergies utilizing the company’s
proprietary T-cell epitope desensitization technology, ToleroMune. The
company is also developing its ToleroTrans organ anti-rejection technology,
which uses a similar approach to down-regulate immune responses in
transplant patients.
Circassia’s anti-allergy products offer potential important clinical
benefits compared with existing therapies, and consequently have
significant market opportunities. Over 150 million people suffer from
allergic rhinitis in the US and Europe and the market for current
treatments is approximately $12 billion per year. The prevalence of cat
allergies is also high, with 1-in-6 Americans and nearly 10% of Europeans
suffering from the condition.
For more information please visit
Circassia Ltd

generic propecia online buy | Buy cialis pills | Buy lasix pills